Hodgkin lymphoma updates in the UK: ECHELON-1

Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, shares some insights into frontline treatment of patients with Hodgkin lymphoma (HL). Dr Osborne first explains the ongoing discussion surrounding the use of escalated BEACOPP versus a standard RATHL approach in the UK. Following this, Dr Osborne highlights the importance of the ECHELON-1 trial (NCT01712490) investigating the use of brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in patients with HL. Results from this trial indicate an overall survival benefit, but Dr Osborne explains that further analysis of the results and a better understanding of the reason behind this survival benefit are important before knowing how this will influence treatment in the UK. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.